Since recombinant erythropoietin is widely used in clinical practice to treat anemia associated with chronic kidney disease in patients who already suffer from compromised bone health, it is advisable to monitor these patients closely, and to minimize the potential adverse skeletal outcomes by administering the lowest effective dose of EPO for the shortest possible time [26]. The gene discussed is EPO; the disease is chronic kidney disease.